Private Placements, Capital Formation,
Restructuring & Recapitalizations



SCOLR, Inc. ~ $15,000,000 Common Stock ~ February 2005

SCOLR, Inc. is a biopharmaceutical company leveraging proprietary, patented technologies in drug delivery to introduce novel prescription drugs, OTC products and dietary supplements. The Company is moving forward with human clinicals for extended release formulations of Ibuprofen, Pseudoephedrine and Raloxifene based on its proprietary CDT® drug delivery platform. SCOLR turned to Taglich Brothers to raise $15 million in a private placement of Common Stock with institutional and accredited individual investors. This additional capital allows the Company to continue is current development plans, seek partnerships with pharmaceutical companies and pursue additional research and development projects to the Company’s advantage. Taglich Brothers' support for SCOLR has grown with the Company and has aligned long-term investors’ interests with that of the Company.

The information contained herein does not constitute a solicitation of any order to buy or sell any securities. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Taglich Brothers, Inc.